Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Short-Term Debt & Capital Lease Obligation : HK$59.5 Mil (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Sichuan Kelun-Biotech Biopharmaceutical Co Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Sichuan Kelun-Biotech Biopharmaceutical Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$59.5 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Sichuan Kelun-Biotech Biopharmaceutical Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$6.0 Mil.

Sichuan Kelun-Biotech Biopharmaceutical Co Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Sichuan Kelun-Biotech Biopharmaceutical Co's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sichuan Kelun-Biotech Biopharmaceutical Co Short-Term Debt & Capital Lease Obligation Chart

Sichuan Kelun-Biotech Biopharmaceutical Co Annual Data

Trend

Dec21

Dec22

Dec23

Short-Term Debt & Capital Lease Obligation

2,926.02

3,320.05

59.51

Sichuan Kelun-Biotech Biopharmaceutical Co Quarterly Data
	Sep21	Dec21	Jun22	Sep22	Dec22	Jun23	Dec23
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial			-	3,259.78	3,320.05	45.07	59.51

Sichuan Kelun-Biotech Biopharmaceutical Co Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Sichuan Kelun-Biotech Biopharmaceutical Co Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Sichuan Kelun-Biotech Biopharmaceutical Co's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sichuan Kelun-Biotech Biopharmaceutical Co Ltd (HKSE:06990) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 666 Xinhua Avenue, Chengdu Cross-Strait Science and Technology Industry Development Park, Wenjiang, Sichuan, Chengdu, CHN

Website

http://www.kelun-biotech.com

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is an innovative biopharmaceutical company committed to the R&D, manufacturing and commercialization of novel drugs to address medical needs in China and globally. It is one of the first movers in the development of antibody-drug conjugates (ADCs), with over a decade of accumulated experience in ADC development. The company takes a systematic, indication-oriented approach to target the world's prevalent or hard-to-treat cancers, and other diseases and conditions affecting a large and underserved population.

Executives

Liu Gexin	2201 Interest of corporation controlled by you
Si Chuan Ke Lun Yao Ye Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you
Cheng Du Ke Lun Jing Chuan Ke Ji You Xian Gong Si	2201 Interest of corporation controlled by you
Wellington Management Group Llp	2102 Investment manager
Merck & Co., Inc.	2201 Interest of corporation controlled by you
Merck Sharp & Dohme Llc	2101 Beneficial owner
Ke Lun Guo Ji Fa Zhan You Xian Gong Si	2101 Beneficial owner
Li Jun	2201 Interest of corporation controlled by you
Zhou Quan	2201 Interest of corporation controlled by you
Idg Breyer Capital Fund Gp Associates L.p.	2201 Interest of corporation controlled by you
Idg Breyer Capital Fund Gp Associates Ltd.	2201 Interest of corporation controlled by you
Idg Breyer Capital Fund L.p.	2201 Interest of corporation controlled by you
Victory Rhythm Limited	2201 Interest of corporation controlled by you
Wealthy Linkage Limited	2101 Beneficial owner
Ho Chi Sing	2201 Interest of corporation controlled by you

Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Headlines

No Headlines